LIM and SH3 protein 1 (LASP-1) expression in clear cell renal cell cancer (ccRCC) tissues and cell lines.

<p>LASP-1 protein expression in paraffin-embedded ccRCC tissues (A) and adjacent nontumorous tissues (B) using immunohistochemistry (magnification, 100×), in which positive LASP-1 immunostaining showed brown color. Wilcoxon analysis demonstrated that tumor tissues showed significantly higher LASP-1 expression than nontumorous tissues (C, n = 216). Western blot (D) and real-time PCR (E, n = 20) analyses confirmed the findings in immunohistochemistry analysis. Western blot analysis also showed differential LASP-1 expression in human embrynal kidney cells (HEK-293) and ccRCC cell lines (F). T refers to tumor tissues, whereas P refers to peritumor (nontumorous) tissues in panel D.</p

LASP-1 silencing inhibited RCC cell migration in vitro.

<p>Western blotting was used to verify knock-down of LASP-1 expression in 786–0 cells by siRNA transfection (A). An unpaired t-test was used to assess differences in the number of invaded cells per field between the 786–0 and si786–0 cell lines (B). Transwell results for the 786–0 and si786–0 cell lines are shown (C).</p

Association between LASP-1 expression and clinical characteristics in ccRCC patients.

<p>Abbreviations: ccRCC, clear cell renal cell cancer; LASP-1, LIM and SH3 protein 1.</p

LIM and SH3 protein 1 (LASP-1) overexpression in clear cell renal cell cancer (ccRCC) is associated with poor overall survival (A) and recurrence free survival (B).

<p>LIM and SH3 protein 1 (LASP-1) overexpression in clear cell renal cell cancer (ccRCC) is associated with poor overall survival (A) and recurrence free survival (B).</p

Univariate Cox regression analysis of the prognostic factors for ccRCC.

<p>Abbreviations: CI, confidence interval; ccRCC, clear cell renal cell cancer; HR, hazard ratio; LASP-1, LIM and SH3 protein 1.</p

Characteristics distribution of study population by recurrence.

<p>*<i>P</i> values were compared by chi-square test for categorical variables and Student’s <i>t</i> test for continuous variable.</p><p>Abbreviations: AFP, α-fetal protein; BCLC, Barcelona Clinic Liver Cancer; HBsAg, hepatitis B virus surface antigen; SD, standard deviation; PVTT, portal vein tumor thrombus; TACE, transcatheter arterial chemoembolization</p><p>Characteristics distribution of study population by recurrence.</p

Cumulative effects of risk genotypes.

<p>A) Overall recurrence free survival; B) Early recurrence free survival. Cumulative effects of risk genotypes groups were assessed by Kaplan-Meier curves (left panels) and estimated using Cox proportional hazards model by multivariate analysis (right panels). Individual SNPs with significant <i>P</i> values <0.05 were included to categorize the risk genotype groups.</p

Modified effects of TACE treatment on HCC recurrence stratified by the number of risk genotypes.

<p>A) In all patients; B) In patients with less than 2 risk genotypes; C) In patients with equal to or more than 2 risk genotypes.</p